Related Experiment Video
Updated: Jul 4, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Translated COOP/WONCA charts found appropriate for use among Turkish and Moroccan ethnic minority cancer patients
Rianne Hoopman1, Caroline B Terwee, Neil K Aaronson
1Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
Objective:
(1) To translate and validate the COOP/WONCA charts in Turkish, Moroccan-Arabic, and Tarifit for use among ethnic minority cancer patients in the Netherlands, and (2) to determine the patient-proxy agreement for Dutch speaking proxies.
Study Design And Setting:
Ninety Turkish patients (with 36 proxies) and 79 Moroccan patients (with 21 proxies) participated in the study. Psychometric evaluation included analysis of feasibility, construct validity, known-groups validity, and responsiveness. Patient-proxy agreement was analyzed at the group and individual level.
Results:
Few missing items were observed. Evidence of construct validity based on comparisons with the SF-36 was relatively strong. Known-groups validity was observed using performance status, comorbidity, and gender as grouping variables, but not using disease stage or treatment status. Moderate responsiveness was observed in the Turkish sample, but not in the Moroccan group. Proxy-patient agreement at the group level was relatively high for all domains, except pain. Agreement at the individual level was poor.
Conclusion:
The results provide relatively strong support for the use of the translated COOP/WONCA charts. However, further work is required to examine responsiveness in the Moroccan patient population. Proxy COOP/WONCA chart ratings may be appropriate at the group level, but not at the individual patient level.
Related Concept Videos
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Treatment Resistant Cancers
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...